AI Insight
Researchers have identified that macrophages, a type of immune cell in the liver, split into two distinct populations during liver fibrosis: one type (SAMs) that promotes scarring and another type (ReM2 cells) that helps resolve it and heal the liver. This divergence explains how the same immune cells can have opposing roles in chronic liver disease progression. The study used mouse models to track how macrophages make this critical decision between promoting damage or facilitating repair.
Why it matters
This discovery could lead to new therapeutic approaches for treating liver fibrosis and chronic liver disease by targeting the mechanisms that determine which type of macrophage develops. Understanding this cellular decision-making process may enable doctors to tip the balance toward healing macrophages and away from scar-promoting ones, potentially providing the first effective treatments for a currently untreatable condition.
Understand the Science
Proceedings of the National Academy of Sciences, Volume 123, Issue 34, August 2026. <br/>SignificanceLiver fibrosis, a scarring process that underlies chronic liver disease, remains untreatable. Macrophages are immune cells that either promote scarring or help the liver heal, but how they decide between these roles is unclear. Using a mouse …
Source: Macrophages diverge into profibrotic SAMs and proresolving ReM2 cells to regulate liver fibrosis